Articles in Scholarly Journals [Incomplete List]

1. Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt
   Bioorganic & Medicinal Chemistry, vol. 15, no. 6, pp. 2441–2452, 2007
2. Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension
   Journal of Medicinal Chemistry, vol. 50, no. 13, pp. 2990–3003, 2007
3. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
   Clinical Cancer Research, vol. 13, no. 9, pp. 2728–2737, 2007
4. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis
   Molecular Cancer Therapeutics, vol. 5, no. 3, pp. 494–501, 2006
5. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors
   Bioorganic & Medicinal Chemistry, vol. 14, no. 20, pp. 6832–6846, 2006
6. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors
   Oncogene, vol. 25, no. 9, Article ID 1209169, 8 pages, 2006
7. Quantitative Analysis of Anti-apoptotic Function of Akt in Akt1 and Akt2 Double Knock-out Mouse Embryonic Fibroblast Cells under Normal and Stressed Conditions
   Journal of Biological Chemistry, vol. 281, no. 42, pp. 31380–31388, 2006
8. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation
   Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 6, pp. 1679–1685, 2006
9. Synthesis and structure–activity relationship of 3,4'-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer
   Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 7, pp. 2000–2007, 2006
10. Isoquinoline–pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity
    Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 12, pp. 3150–3155, 2006
11. Discovery and SAR of oxindole–pyridine-based protein kinase B/Akt inhibitors for treating cancers
    Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 13, pp. 3424–3429, 2006
12. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase
    Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 14, pp. 3740–3744, 2006
13. Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals
    Cancer Research, vol. 65, no. 7, pp. 2698–2704, 2005
14. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response
    Expert Review of Anticancer Therapy, vol. 5, no. 2, pp. 333–342, 2005
15. Optimal Classes of Chemotherapeutic Agents Sensitized by Specific Small-Molecule Inhibitors of Akt In Vitro and In Vivo
    Neoplasia, vol. 7, no. 11, pp. 992–1000, 2005
16. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
    Molecular Cancer Therapeutics, vol. 4, no. 6, pp. 977–986, 2005
17. Biochemistry, vol. 43, no. 5, pp. 1254–1263, 2004
18. Downregulation of Akt1 Inhibits Anchorage-Independent Cell Growth and Induces Apoptosis in Cancer Cells
    Neoplasia, vol. 3, no. 4, Article ID 7900163, 8 pages, 2001
19. Blocking CHK1 Expression Induces Apoptosis and Abrogates the G2 Checkpoint Mechanism
    Neoplasia, vol. 3, no. 5, Article ID 7900175, 8 pages, 2001